The European Commission has granted Orphan Medicinal Product designation for zatolmilast an investigational treatment for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.
Adragos Pharma is a contract development and manufacturing organization (CDMO) that provides development and manufacturing services for drug products. It concentrates on small molecule dosage forms including sterile and non-sterile liquids, solids, and semi-solids products.
In a groundbreaking revelation, a study conducted by RCSI University of Medicine and Health Sciences and Children’s Health Ireland has confirmed the safety and efficacy of a Cystic Fibrosis drug in newborns as young as four weeks old.